Indiana University Vector Production Facility

Indianapolis, IN
National Center
AAV Lentiviral
45 confirmed programs · 10 sponsors · Last scored 2026-04-29
66.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (45) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Indiana University Vector Production Facility

Signal Score
66.3/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Indianapolis, IN
Modalities
AAV, Lentiviral
Active Programs
45 confirmed from ClinicalTrials.gov across 10 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Indiana University Vector Production Facility

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 71.6
45 active programs across 10 sponsors
Modalities: AAV, Lentiviral
16 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
45 active programs across 10 sponsors · Modalities: AAV, Lentiviral · 16 programs in advanced phases (Phase 2/3)
Programs 45
Sponsors10
ModalitiesAAV, Lentiviral
45 active programs across 10 sponsors
Modalities: AAV, Lentiviral
16 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting
NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting
NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting
NCT06508827 Intravenous Iron in Combination With Standard of Care... PHASE2 Withdrawn
NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated
NCT05757843 Using Circulating Tumor DNA to Personalize Duration of... PHASE2 Withdrawn
NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in... NA Recruiting
NCT06511453 Acupressure in Patients With Sickle Cell Disease NA Active Not Recruiting
NCT04402593 Music Therapy For The Treatment Of Cisplatin Induced Tinnitus... NA Withdrawn
NCT05783297 Midwest TXTXT Scale up of an Evidence-Based Intervention to... NA Active Not Recruiting
View all 45 programs →
Source: ClinicalTrials.gov · Retrieved May 20, 2026
Financial Stability 68.0
Parent company: Indiana University
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Indiana University
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

Clinical Activity 45 studies

NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting NCT06508827 Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma PHASE2 Withdrawn NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated NCT05757843 Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab PHASE2 Withdrawn NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes NA Recruiting NCT06511453 Acupressure in Patients With Sickle Cell Disease NA Active Not Recruiting NCT04402593 Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients... NA Withdrawn NCT05783297 Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV... NA Active Not Recruiting NCT05100342 Prospective Validation of a Points Score System Predicting 30-day Survival NA Recruiting NCT05119036 Adjuvant Treatment Deintensification After Transoral Surgery for Human... NA Active Not Recruiting NCT05251337 Use of Aromatherapy to Reduce Symptom Burden PHASE2 Completed NCT03321760 SABR for T1-2a N1 NSCLC PHASE2 Withdrawn NCT04930055 Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC) NA Terminated NCT05045820 Integrative Medicine in Pain Management in Sickle Cell Disease NA Active Not Recruiting NCT04309370 Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate... NA Completed NCT03997903 Imatinib for Pain in Sickle Cell Anemia PHASE1/PHASE2 Terminated NCT04187768 Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer NA Completed NCT03789864 Biodynamic Imaging Utility in Predicting Response to Gemcitabine... NA Terminated
+ 25 more studies
Source: ClinicalTrials.gov · Retrieved May 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Genezen
Indianapolis, IN · Lexington, MA
Signal Score: 70.7
AAV, Lentiviral
CoJourney Inc.
Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)
Plasmid DNA, AAV, Adenoviral, Lentiviral, Retroviral, mRNA, sgRNA, Exosome
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid